bio chat
just beginning to adopt
NGS methods.
that the overall amount
of sequencing data that is
generated in the clinical
diagnostic space will
increase dramatically.
Unfortunately, clinical
diagnostics sequencing
is just the first step of the
process. The generated
data needs to be analyzed
by bioinformatics tools
and the right variant
needs to be identified
amongst the thousands
(or millions) of variants
detected in the sample.
While sequencing a whole
genome at $100 may be
possible in the next few
years, interpreting the
data remains a million-
dollar problem and Strand
36
BioVoiceNews | May 2017
has made significant
strides towards reducing
the post-sequencing cost
of testing.
Strand NGS 3.0 allows
users to analyze data at
nearly twice the speed
of the most commonly
used pipeline, reduces
storage costs by nearly
60%, provides managed
storage and in-built
visualizations for variant
verification - all without
sacrificing accuracy. The
user-friendly interface
of Strand NGS insulates
users from the complexity
of NGS analysis and
makes large panel
analysis easy even for
pathology labs which are
The combination of
Strand NGS, our vast
curated information,
and our interpretation
and reporting software,
which are all part of
Strand Ramanujan, can
aid in speedy adoption
of NGS in clinical
diagnostic laboratories
world-wide. Therefore,
through recombinant
innovation, companies
like Strand from India
are contributing by
adding layers of world
class bioinformatics and
AI platforms to bring in
“affordable excellence” in
genomic testing.
Please tell us more
about your plans
to build a clinical
genomics database for
genomics medicine in
oncology? What will
be its impact?
Strand carries out
multiple molecular tests
that cover the entire
oncology spectrum -
hereditary cancer risk
prediction, somatic tumor
profiling and therapy
recommendations, and
recently introduced